Vanda Pharmaceuticals (VNDA) Reports In-Line Q1 EPS, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/27/2024
- Wall Street shares close up as megacap tech stocks rally
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil settles higher on supply concerns in the Mideast, economic woes subdue gains
- 'This is Enron:' Facebook and Asana co-founder accuses Tesla of 'massive' fraud
- Vietnam delays launch of new stock trading system
- Wall Street shares close up as megacap tech stocks rally
- Biden appears in live interview with Howard Stern
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- Midday movers: Alphabet, Microsoft and Snap rise; Intel, Hertz Global fall
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results
May 5, 2021 4:01 PM EDTWASHINGTON, May 5, 2021 /PRNewswire/ --Â Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2021.
"Despite seasonal and global challenges, we recorded another quarter of strong revenue across our commercial portfolio coupled with the launch of HETLIOZ® in the new indication of nighttime sleep disturbances in patients with Smith-Magenis Syndrome," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda. "In our clinical programs, we have made significant progress, reaching 85% randomization in our Phase III tradipitant study in gastroparesis and initiating... More
